RESUMEN
A series of 3-aminopyrrolidine-2,5-dione derivatives was synthesized and tested for anticonvulsant activity. Succinimide derivatives were obtained from a simple solvent-based reaction and a mechanochemical aza-Michael reaction of maleimide or its N-substituted derivatives with selected amines. The structure of the compounds was confirmed by spectroscopic methods (NMR, FT-IR, HPLC, ESI-MS, EA and XRD for four compounds). The cytotoxic activity of the succinimide derivatives was evaluated using HepG2 cells for hepatocytotoxicity and SH-SY5Y cells for neurocytotoxicity. None of the studied compounds showed hepatocytotoxicity and two showed neurocytotoxicity. Initial anticonvulsant screening was performed in mice using the psychomotor seizure test (6 Hz, 32 mA). The selected compounds were evaluated in the following acute models of epilepsy: the maximal electroshock test, psychomotor seizure test (6 Hz, 44 mA), subcutaneous pentylenetetrazole seizure test, and acute neurotoxicity (rotarod test). The most active compound 3-((4-chlorophenyl)amino)pyrrolidine-2,5-dione revealed antiseizure activity in all seizure models (including pharmacoresistant seizures) and showed better median effective doses (ED50) and protective index values than the reference compound, ethosuximide. Furthermore, 3-(benzylamino)pyrrolidine-2,5-dione and 3-(phenylamino)pyrrolidine-2,5-dione exhibited antiseizure activity in the 6 Hz and MES tests, and 3-(butylamino)-1-phenylpyrrolidine-2,5-dione and 3-(benzylamino)-1-phenylpyrrolidine-2,5-dione exhibited antiseizure activity in the 6 Hz test. All active compounds demonstrated low in vivo neurotoxicity in the rotarod test and yielded favourable protective indices.
Asunto(s)
Anticonvulsivantes , Neuroblastoma , Humanos , Ratones , Animales , Anticonvulsivantes/farmacología , Anticonvulsivantes/uso terapéutico , Anticonvulsivantes/química , Espectroscopía Infrarroja por Transformada de Fourier , Neuroblastoma/tratamiento farmacológico , Convulsiones/tratamiento farmacológico , Convulsiones/prevención & control , Etosuximida/uso terapéutico , Pentilenotetrazol , Relación Estructura-Actividad , Estructura MolecularRESUMEN
The adenosine A2A and A2B receptors are promising therapeutic targets in the treatment of obesity and diabetes since the agonists and antagonists of these receptors have the potential to positively affect metabolic disorders. The present study investigated the link between body weight reduction, glucose homeostasis, and anti-inflammatory activity induced by a highly potent and specific adenosine A2B receptor antagonist, compound PSB-603. Mice were fed a high-fat diet for 14 weeks, and after 12 weeks, they were treated for 14 days intraperitoneally with the test compound. The A1/A2A/A2B receptor antagonist theophylline was used as a reference. Following two weeks of treatment, different biochemical parameters were determined, including total cholesterol, triglycerides, glucose, TNF-α, and IL-6 blood levels, as well as glucose and insulin tolerance. To avoid false positive results, mouse locomotor and spontaneous activities were assessed. Both theophylline and PSB-603 significantly reduced body weight in obese mice. Both compounds had no effects on glucose levels in the obese state; however, PSB-603, contrary to theophylline, significantly reduced triglycerides and total cholesterol blood levels. Thus, our observations showed that selective A2B adenosine receptor blockade has a more favourable effect on the lipid profile than nonselective inhibition.
Asunto(s)
Enfermedades Metabólicas , Antagonistas de Receptores Purinérgicos P1 , Animales , Ratones , Adenosina/farmacología , Antagonistas del Receptor de Adenosina A2/farmacología , Antagonistas del Receptor de Adenosina A2/uso terapéutico , Antagonistas del Receptor de Adenosina A2/metabolismo , Peso Corporal , Colesterol/uso terapéutico , Glucosa/metabolismo , Obesidad/tratamiento farmacológico , Obesidad/metabolismo , Nucleósidos de Purina , Antagonistas de Receptores Purinérgicos P1/uso terapéutico , Receptor de Adenosina A2B/metabolismo , Teofilina , Triglicéridos/uso terapéuticoRESUMEN
The present study aimed to design and synthesize a series of 2-hydroxy-3-(4-aryl-1-piperazinyl)propyl phthalimide derivatives, which are analogs of 1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives with proven analgesic effect. In accordance with the basic principle proposed by Lipinski's rule, the probable bioavailabilities of the F1-F4 phthalimides were assessed. The obtained values indicate good absorption after oral administration and the ability to cross the blood-brain barrier. The four compounds F1-F4 differing in the type of pharmacophore in the phenyl group of the 2-hydroxy-3-(4-aryl-1-piperazinyl)propyl on the imide nitrogen atom (R, F1-F3) and the 4-benzhydryl analog (F4) were selected for in vitro and in vivo studies. Based on the in vitro studies, the effects of compounds F1-F4 on cell viability/proliferation and COX-2 levels were evaluated. Moreover, using in vivo methods, the compounds were tested for antinociceptive activity in models of acute pain (the writhing and the hot-plate tests) in mice. Their influence on the motor coordination effect and locomotor activity was also tested. The obtained results revealed that the compounds F1-F4 strongly suppress the pain of peripheral origin and to a lesser extent (F1-F3) pain of central/supraspinal origin. In the in vitro studies, F1-F4 reduced the COX-2 level in lipopolysaccharide-activated RAW 264.7 cells, which suggests their anti-inflammatory activity.
Asunto(s)
Analgésicos , Dolor , Animales , Ciclooxigenasa 2 , Ratones , Dolor/tratamiento farmacológico , Dimensión del Dolor , Relación Estructura-ActividadRESUMEN
Antiseizure drugs (ASDs) are commonly used to treat a wide range of nonepileptic conditions, including pain. In this context, the analgesic effect of four pyrrolidine-2,5-dione derivatives (compounds 3, 4, 6, and 9), with previously confirmed anticonvulsant and preliminary antinociceptive activity, was assessed in established pain models. Consequently, antinociceptive activity was examined in a mouse model of tonic pain (the formalin test). In turn, antiallodynic and antihyperalgesic activity were examined in the oxaliplatin-induced model of peripheral neuropathy as well as in the streptozotocin-induced model of painful diabetic neuropathy in mice. In order to assess potential sedative properties (drug safety evaluation), the influence on locomotor activity was also investigated. As a result, three compounds, namely 3, 6, and 9, demonstrated a significant antinociceptive effect in the formalin-induced model of tonic pain. Furthermore, these substances also revealed antiallodynic properties in the model of oxaliplatin-induced peripheral neuropathy, while compound 3 attenuated tactile allodynia in the model of diabetic streptozotocin-induced peripheral neuropathy. Apart from favorable analgesic properties, the most active compound 3 did not induce any sedative effects at the active dose of 30 mg/kg after intraperitoneal (i.p.) injection.
Asunto(s)
Neuropatías Diabéticas , Neuralgia , Analgésicos/farmacología , Analgésicos/uso terapéutico , Animales , Neuropatías Diabéticas/tratamiento farmacológico , Modelos Animales de Enfermedad , Hiperalgesia/tratamiento farmacológico , Ratones , Neuralgia/tratamiento farmacológico , Oxaliplatino/uso terapéutico , Pirrolidinas , EstreptozocinaRESUMEN
The complex pathophysiology of depression, together with the limits of currently available antidepressants, has resulted in the continuous quest for alternative therapeutic strategies. Numerous findings suggest that pharmacological blockade of α2-adrenoceptor might be beneficial for the treatment of depressive symptoms by increasing both norepinephrine and serotonin levels in certain brain areas. Moreover, the antidepressant properties of 5-HT7 receptor antagonists have been widely demonstrated in a large set of animal models. Considering the potential therapeutic advantages in targeting both α2-adrenoceptors and 5-HT7 receptors, we designed a small series of arylsulfonamide derivatives of (dihydrobenzofuranoxy)ethyl piperidines as dually active ligands. Following green chemistry principles, the designed compounds were synthesized entirely using a sustainable mechanochemical approach. The identified compound 8 behaved as a potent α2A/5-HT7 receptor antagonist and displayed moderate-to-high selectivity over α1-adrenoceptor subtypes and selected serotonin and dopaminergic receptors. Finally, compound 8 improved performance of mice in the forced swim test, displaying similar potency to the reference drug mirtazapine.
Asunto(s)
Antagonistas de Receptores Adrenérgicos alfa 2/química , Antagonistas de Receptores Adrenérgicos alfa 2/farmacología , Antidepresivos/farmacología , Depresión/tratamiento farmacológico , Actividad Motora/efectos de los fármacos , Receptores Adrenérgicos alfa 2/metabolismo , Receptores de Serotonina/metabolismo , Antagonistas de Receptores Adrenérgicos alfa 2/síntesis química , Antagonistas de Receptores Adrenérgicos alfa 2/uso terapéutico , Animales , Antidepresivos/uso terapéutico , Escala de Evaluación de la Conducta , Depresión/fisiopatología , Células HEK293 , Humanos , Ligandos , Masculino , Ratones , Mirtazapina/farmacología , Mirtazapina/uso terapéutico , Norepinefrina/metabolismo , Piperidinas/química , Ratas , Receptores de Serotonina/genética , Serotonina/metabolismo , NataciónRESUMEN
A2B adenosine receptors are present in a wide spectrum of tissues, especially on cells of the immune system. Since these particular receptors have the lowest, of all adenosine receptor subtypes, affinity for adenosine they are believed to play a special role in immunological processes associated with elevated adenosine levels such as inflammation. The aim of this preliminary study was to determine the potential anti-inflammatory properties of compound PSB-603, a potent and selective adenosine A2B receptor antagonist, in two different experimental models of local and systemic inflammation. In a model of inflammation induced by local carrageenan administration paw edema was measured using a pletysmometer. Additionally, levels of C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α) and reactive oxygen species (ROS) were determined in the inflamed paw. Using the mouse model of peripheral inflammation induced by intraperitoneal (ip) administration of zymosan A, the influence of the A2B antagonist on the infiltration of neutrophils into the peritoneum and its effect on the plasma levels of CRP, TNF-α, and IL-6 were investigated. The results showed that PSB-603 administered at a dose of 5 mg/kg b.w. ip significantly reduced inflammation in both tested models. Particularly, it significantly decreased levels of the inflammatory cytokines IL-6, TNF-α and of ROS in the inflamed paw and reduced inflammation of the peritoneum by significantly decreasing the infiltration of leukocytes. Additionally, in the latter model, no statistically significant difference was observed in the CRP level between the control group without inflammation and the group which has been treated with the PSB-603 compound. Thus, the results may indicate the anti-inflammatory activity of adenosine A2B receptor antagonists in two different models of inflammation.
Asunto(s)
Antagonistas del Receptor de Adenosina A2/farmacología , Antiinflamatorios/farmacología , Citocinas/metabolismo , Mediadores de Inflamación/metabolismo , Inflamación/prevención & control , Receptor de Adenosina A2B/efectos de los fármacos , Sulfonamidas/farmacología , Xantinas/farmacología , Animales , Carragenina , Modelos Animales de Enfermedad , Inflamación/inducido químicamente , Inflamación/metabolismo , Masculino , Ratones , Especies Reactivas de Oxígeno/metabolismo , Receptor de Adenosina A2B/metabolismo , Transducción de Señal , ZimosanRESUMEN
The present study aimed to design and synthesize a new series of hybrid compounds with pyrrolidine-2,5-dione and thiophene rings in the structure as potential anticonvulsant and antinociceptive agents. For this purpose, we obtained a series of new compounds and evaluated their anticonvulsant activity in animal models of epilepsy (maximal electroshock (MES), psychomotor (6 Hz), and subcutaneous pentylenetetrazole (scPTZ) seizure tests). To determine the mechanism of action of the most active anticonvulsant compounds (3, 4, 6, 9), their influence on the voltage-gated sodium and calcium channels as well as GABA transporter (GAT) was assessed. The most promising compound 3-(3-methylthiophen-2-yl)-1-(3-morpholinopropyl)pyrrolidine-2,5-dione hydrochloride (4) showed higher ED50 value than those of the reference drugs: valproic acid (VPA) and ethosuximide (ETX) (62.14 mg/kg vs. 252.7 mg/kg (VPA) in the MES test, and 75.59 mg/kg vs. 130.6 mg/kg (VPA) and 221.7 mg/kg (ETX) in the 6 Hz test, respectively). Moreover, in vitro studies of compound 4 showed moderate but balanced inhibition of the neuronal voltage-sensitive sodium (site 2) and L-type calcium channels. Additionally, the antinociceptive activity of the most active compounds (3, 4, 6, 9) was also evaluated in the hot plate test and writhing tests, and their hepatotoxic properties in HepG2 cells were also investigated. To determine the possible mechanism of the analgesic effect of compounds 3, 6, and 9, the affinity for the TRPV1 receptor was investigated.
Asunto(s)
Analgésicos/síntesis química , Analgésicos/farmacología , Anticonvulsivantes/síntesis química , Anticonvulsivantes/farmacología , Pirrolidinas/síntesis química , Pirrolidinas/farmacología , Analgésicos/química , Animales , Anticonvulsivantes/química , Supervivencia Celular/efectos de los fármacos , Células Hep G2 , Humanos , Masculino , Ratones , Pirrolidinas/químicaRESUMEN
The A2 adenosine receptors play an important role, among others, in the regulation of inflammatory process and glucose homeostasis in diabetes and obesity. Thus, the presented project evaluated of influence of the selective antagonist of A2A adenosine receptor-KD-64 as compared to the known non-selective antagonist-caffeine on these two particular processes. Two different inflammation models were induced namely local and systemic inflammation. Obesity was induced in mice by high-fat diet and the tested compounds (KD-64 and caffeine) were administrated for 21 days. KD-64 showed anti-inflammatory effect in both tested inflammation models and administered at the same dose as ketoprofen exerted stronger effect than this reference compound. Elevated levels of IL-6 and TNF-α observed in obese control mice were significantly lowered by the administration of KD-64 and were similar to the values observed in control non-obese mice. Interestingly, caffeine increased the levels of these parameters. In contrast to caffeine which had no influence on AlaT activity, KD-64 administration significantly lowered AlaT activity in the obese mice. Although, contrary to caffeine, KD-64 did not reduce diet-induced obesity in mice, it improved glucose tolerance. Thus, the activity of the selective adenosine A2A receptor antagonist was quite different from that of the non-selective.
Asunto(s)
Antagonistas del Receptor de Adenosina A2/farmacología , Antiinflamatorios/farmacología , Dieta/efectos adversos , Antagonistas del Receptor de Adenosina A2/uso terapéutico , Animales , Antiinflamatorios/uso terapéutico , Peso Corporal/efectos de los fármacos , Cafeína/farmacología , Permeabilidad Capilar/efectos de los fármacos , Dieta Alta en Grasa/efectos adversos , Resistencia a la Insulina , Interleucina-6/sangre , Locomoción/efectos de los fármacos , Masculino , Ratones , Obesidad/inducido químicamente , Obesidad/tratamiento farmacológico , Peritoneo/efectos de los fármacos , Factor de Necrosis Tumoral alfa/sangreRESUMEN
The aim of the presented study was to examine the potential antinociceptive, antiedematous (anti-inflammatory), and antiallodynic activities of two 1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dione derivatives (DSZ 1 and DSZ 3) in various experimental models of pain. For this purpose, the hot plate test, the capsaicin test, the formalin test, the carrageenan model, and oxaliplatin-induced allodynia tests were performed. In the hot plate test, only DSZ 1 in the highest dose (20 mg/kg) was active but its effects appear to be due to sedatation rather than antinociceptiveness. In capsaicin-induced neurogenic pain model, both compounds displayed a significant antinociceptive activity. In the formalin test, DSZ 1 and DSZ 3 (5-20 mg/kg) revealed antinociceptive activity in both phases but it was more pronounced in the second phase of the test. In this test, pretreatment with caffeine, DPCPX reversed the antinociceptive effect of DSZ 3. On the other hand, pretreatment with L-NAME diminished the antinociceptive effect of DSZ 1. Pretreatment with naloxone did not affect antinociceptive activity of both compounds. Similar to ketoprofen, DSZ 1 and DSZ 3 showed antiedematous (antiinflammatory) and antihyperalgesic activity, and similar to lidocaine local anesthetic activity. Furthermore, both compounds (5 and 10 mg/kg) reduced tactile allodynia in acute and chronic phases of neuropathic pain. In the in vitro studies, DSZ 1 and DSZ 3 reduced the COX-2 level in LPS-activated RAW 264.7 cells, which suggests their anti-inflammatory activity. In conclusion, both DSZ 1 and DSZ 3 displayed broad spectrum of activity in several pain models, including neurogenic, tonic, inflammatory, and chemotherapy-induced peripheral neuropathic pain.
Asunto(s)
Analgésicos/farmacología , Antiinflamatorios/farmacología , Edema/prevención & control , Hiperalgesia/prevención & control , Dolor Nociceptivo/prevención & control , Umbral del Dolor/efectos de los fármacos , Piridonas/farmacología , Analgésicos/síntesis química , Animales , Antiinflamatorios/síntesis química , Ciclooxigenasa 2/metabolismo , Modelos Animales de Enfermedad , Edema/metabolismo , Edema/fisiopatología , Hiperalgesia/metabolismo , Hiperalgesia/fisiopatología , Locomoción/efectos de los fármacos , Macrófagos/efectos de los fármacos , Macrófagos/enzimología , Masculino , Ratones , Óxido Nítrico/metabolismo , Dolor Nociceptivo/metabolismo , Dolor Nociceptivo/fisiopatología , Piridonas/síntesis química , Células RAW 264.7 , Ratas Wistar , Receptor de Adenosina A1/metabolismo , Transducción de SeñalRESUMEN
BACKGROUND: It has recently been suggested that the adenosine A2A receptor plays a role in several animal models of depression. Additionally, A2A antagonists have reversed behavioral deficits and exhibited a profile similar to classical antidepressants. METHODS: In the present study, imidazo- and pyrimido[2,1-f]purinedione derivatives (KD 66, KD 167, KD 206) with affinity to A2A receptors but poor A1 affinity were evaluated for their antidepressant- and anxiolytic-like activity. The activity of these derivatives was tested using a tail suspension and forced swim test, two widely-used behavioral paradigms for the evaluation of antidepressant-like activity. In turn, the anxiolytic activity was evaluated using the four-plate test. RESULTS: The results showed the antidepressant-like activity of pyrimido- and imidazopurinedione derivatives (i.e. KD 66, KD 167 and KD 206) in acute and chronic behavioral tests in mice. KD 66 revealed an anxiolytic-like effect, while KD 167 increased anxiety behaviors. KD 206 had no effect on anxiety. Furthermore, none of the tested compounds increased locomotor activity. CONCLUSION: Available data support the proposition that the examined compounds with adenosine A2A receptor affinity may be an interesting target for the development of antidepressant and/or anxiolytic agents.
Asunto(s)
Ansiolíticos/metabolismo , Ansiolíticos/uso terapéutico , Antidepresivos/metabolismo , Antidepresivos/uso terapéutico , Purinérgicos/metabolismo , Purinérgicos/uso terapéutico , Animales , Ansiolíticos/química , Antidepresivos/química , Ansiedad/tratamiento farmacológico , Ansiedad/metabolismo , Ansiedad/psicología , Depresión/tratamiento farmacológico , Depresión/metabolismo , Depresión/psicología , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Inmovilización/métodos , Inmovilización/psicología , Masculino , Ratones , Purinérgicos/químicaRESUMEN
Depression is one of the most common mental disorders and social issue worldwide. Although there are many antidepressants available, the effectiveness of the therapy is still a serious issue. Moreover, there are many limitations of currently used antidepressants, including slow onset of action, numerous side effects, or the fact that many patients do not respond adequately to the treatment. Therefore, scientists are searching for new compounds with different mechanisms of action. Numerous data indicate the important role of glutamatergic, GABA-ergic, and cholinergic receptors in the pathomechanism of major depressive disorder. This review presents the role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect.
Asunto(s)
Antidepresivos/metabolismo , Depresión/metabolismo , Receptores Colinérgicos/metabolismo , Receptores de GABA/metabolismo , Receptores de Glutamato/metabolismo , Animales , HumanosRESUMEN
BACKGROUND: Tiagabine, a selective inhibitor of GABA transporter subtype 1 is used as an add-on therapy of partial seizures in humans but its mechanism of action suggests other potential medical indications for this drug. In this research we assess its pharmacological activity in several screening models of seizures, pain, anxiety and depression in mice. METHODS: For pharmacological tests tiagabine was administered intraperitoneally 60 min before the assay. Behavioral tests were performed using models of chemically and electrically induced seizures, thermal acute pain and formalin-induced tonic pain. Anxiolytic-like properties were evaluated using the four plate test and the elevated plus maze test. Antidepressant-like activity was assessed in the forced swim test. In addition, to exclude false positive results in these assays, the influence of tiagabine on animals' locomotor activity and motor coordination was investigated, too. RESULTS: Tiagabine demonstrated anticonvulsant properties in chemically induced seizures (pentylenetetrazole and pilocarpine seizures). At the dose of 100mg/kg it also elevated the seizure threshold for electrically induced seizures by 31.6% (p<0.01), but it had no activity in the maximal electroshock seizure test. Tiagabine showed anxiolytic-like and antidepressant-like effects. Although it apparently reduced animals' nociceptive responses in pain tests, these activities rather resulted from its sedative and motor-impairing properties demonstrated in the locomotor activity and the rotarod tests, respectively. CONCLUSIONS: The results obtained in the present study suggest that tiagabine, apart its anticonvulsant effect, has anxiolytic-like, sedative and antidepressant-like properties. In view of this, it can be potentially used in the treatment of anxiety and mood disorders.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Ansiedad/tratamiento farmacológico , Depresión/tratamiento farmacológico , Proteínas Transportadoras de GABA en la Membrana Plasmática , Ácidos Nipecóticos/uso terapéutico , Dolor/tratamiento farmacológico , Animales , Ansiedad/psicología , Depresión/psicología , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Masculino , Ratones , Dolor/psicología , Convulsiones/tratamiento farmacológico , Convulsiones/psicología , TiagabinaRESUMEN
Depression is a frequent comorbid disorder in Parkinson's disease and may antedate its motor symptoms. However, mechanisms underlying Parkinson's disease-associated depression are unknown and its current medication is insufficient. The aim of the present study was to compare antidepressant-like effects of imipramine, fluoxetine and pramipexole in a model of preclinical stages of Parkinson's disease in rats. 6-Hydroxydopamine was bilaterally injected into the ventrolateral region of the caudate-putamen in rats. This treatment induced moderate decreases in the levels of dopamine and its metabolites in the caudate-putamen, nucleus accumbens and frontal cortex and reduced the density of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra pars compacta and ventral tegmental area. The lesion increased immobility measured in the forced swimming test without influencing locomotor activity. Chronic (13 days) administration of pramipexole (1mg/kg sc/twice a day) reversed prolongation of the immobility time in lesioned animals but did not stimulate their locomotion. Chronic pramipexole activated dopaminergic transmission in the brain structures which might contribute to its effectiveness in the forced swimming test. In contrast, the 13-day administration of imipramine (10mg/kg ip/day) and fluoxetine (10mg/kg ip/day) did not shorten the immobility time in lesioned rats but reduced their locomotion. The present study indicates that already a moderate lesion of dopaminergic neurons induces "depressive-like" behaviour in animals which is reversed by chronic administration of the antiparkinsonian drug, pramipexole.
Asunto(s)
Benzotiazoles/farmacología , Depresión/tratamiento farmacológico , Agonistas de Dopamina/farmacología , Enfermedad de Parkinson/complicaciones , Animales , Antidepresivos/farmacología , Depresión/etiología , Depresión/psicología , Modelos Animales de Enfermedad , Fluoxetina/farmacología , Imipramina/farmacología , Masculino , Actividad Motora/efectos de los fármacos , Oxidopamina/envenenamiento , Enfermedad de Parkinson/psicología , Pramipexol , Ratas , Ratas Wistar , Natación/psicología , Resultado del TratamientoRESUMEN
It has been shown that a decreased vesicular monoamine transporter (VMAT2) function and the disruption of dopamine (DA) storage is an early contributor to oxidative damage of dopamine neurons in Parkinson's disease (PD). In our previous study, we demonstrated that adenosine A(2A) receptor antagonists suppressed oxidative stress in 6-hydroxydopamine-treated rats suggesting that this effect may account for neuroprotective properties of drugs. In the present study, rats were injected with reserpine (10 mg/kg sc) and 18 h later the effect of the adenosine A(2A) receptor antagonists 8-(3-chlorostyryl)caffeine (CSC) and 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM 241385) on extracellular DA, glutamate and hydroxyl radical formation was studied in the rat striatum using in vivo microdialysis. By disrupting VMAT2 function, reserpine depleted DA stores, and increased glutamate and hydroxyl radical levels in the rat striatum. CSC (1 mg/kg) but not ZM 241385 (3 mg/kg) increased extracellular DA level and production of hydroxyl radical in reserpinised rats. Both antagonists decreased the reserpine-induced increase in extracellular glutamate. L-3,4-Dihydroxyphenylalanine (L-DOPA) (25 mg/kg) significantly enhanced extracellular DA, had no effect on reserpine-induced hydroxyl radical production and decreased extracellular glutamate concentration. CSC but not ZM 241385 given jointly with L-DOPA increased the effect of L-DOPA on extracellular DA and augmented the reserpine-induced hydroxyl radical production. CSC and ZM 241385 did not influence extracellular glutamate level, which was decreased by L-DOPA. It seems that by decreasing the MAO-dependent DA metabolism rate, CSC raised cytosolic DA and by DA autoxidation, it induced hydroxyl radical overproduction. Thus, the methylxanthine A(2A) receptor antagonists bearing properties of MAO-B inhibitor, like CSC, may cause a risk of oxidative stress resulting from dysfunctional DA storage mechanism in early PD.
Asunto(s)
Antagonistas del Receptor de Adenosina A2/farmacología , Cuerpo Estriado/metabolismo , Dopamina/metabolismo , Ácido Glutámico/metabolismo , Radical Hidroxilo/metabolismo , Proteínas de Transporte Vesicular de Monoaminas/fisiología , Ácido 3,4-Dihidroxifenilacético/metabolismo , Inhibidores de Captación Adrenérgica/toxicidad , Animales , Cafeína/análogos & derivados , Cafeína/farmacología , Cuerpo Estriado/efectos de los fármacos , Dopaminérgicos/toxicidad , Espacio Extracelular/efectos de los fármacos , Espacio Extracelular/metabolismo , Ácido Homovanílico/metabolismo , Levodopa/toxicidad , Masculino , Microdiálisis , Estrés Oxidativo/efectos de los fármacos , Ratas , Ratas Wistar , Reserpina/toxicidad , Triazinas/farmacología , Triazoles/farmacología , Proteínas de Transporte Vesicular de Monoaminas/genéticaRESUMEN
A(2A) adenosine receptor antagonists have been proposed as a new therapy of PD. Since oxidative stress plays an important role in the pathogenesis of PD, we studied the effect of the selective A(2A) adenosine receptor antagonists 8-(-3-chlorostyryl)caffeine (CSC) and 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM 241385) on hydroxyl radical generation, and glutamate (GLU) and dopamine (DA) extracellular level using a microdialysis in the striatum of 6-OHDA-treated rats. CSC (1 mg/kg) and ZM 241385 (3 mg/kg) given repeatedly for 14 days decreased the production of hydroxyl radical and extracellular GLU level, both enhanced by prior 6-OHDA treatment in dialysates from the rat striatum. CSC and ZM 241385 did not affect DA and its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanilic acid (HVA) extracellular levels in the striatum of 6-OHDA-treated rats. L-DOPA (6 mg/kg) given twice daily for two weeks in the presence of benserazide (3 mg/kg) decreased striatal hydroxyl radical and glutamate extracellular level in 6-OHDA-treated rats. At the same time, L-DOPA slightly but significantly increased the extracellular levels of DOPAC and HVA. A combined repeated administration of L-DOPA and CSC or ZM 241385 did not change the effect of L-DOPA on hydroxyl radical production and glutamate extracellular level in spite of an enhancement of extracellular DA level by CSC and elevation of extracellular level of DOPAC and HVA by ZM 241385. The data suggest that the 6-OHDA-induced damage of nigrostriatal DA-terminals is related to oxidative stress and excessive release of glutamate. Administration of L-DOPA in combination with CSC or ZM 241385, by restoring striatal DA-glutamate balance, suppressed 6-OHDA-induced overproduction of hydroxyl radical.
Asunto(s)
Ácido 3,4-Dihidroxifenilacético/farmacología , Antagonistas del Receptor de Adenosina A2/farmacología , Radical Hidroxilo/metabolismo , Levodopa/farmacología , Neostriado/metabolismo , Trastornos Parkinsonianos/metabolismo , Animales , Benserazida/farmacología , Cafeína/análogos & derivados , Cafeína/farmacología , Dopamina/metabolismo , Ácido Glutámico/metabolismo , Masculino , Microdiálisis , Oxidopamina , Ratas , Ratas Wistar , Receptor de Adenosina A2A/metabolismo , Triazinas/farmacología , Triazoles/farmacologíaRESUMEN
Abundant evidence suggests that indirect inhibitory modulation of glutamatergic transmission, via metabotropic glutamatergic receptors (mGluR), may induce neuroprotection. The present study was designed to determine whether the selective antagonist of mGluR1 (3-ethyl-2-methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)-methanone methanesulfonate (EMQMCM), showed neuroprotection against the kainate (KA)-induced excitotoxicity in vitro and in vivo. In in vitro studies on mouse primary cortical and hippocampal neuronal cultures, incubation with KA (150 µM) induced strong degeneration [measured as lactate dehydrogenase (LDH) efflux] and apoptosis (measured as caspase-3 activity). EMQMCM (0.1-100 µM) added 30 min to 6 h after KA, significantly attenuated the KA-induced LDH release and prevented the increase in caspase-3 activity in the cultures. Those effects were dose- and time-dependent. In in vivo studies KA (2.5 nmol/1 µl) was unilaterally injected into the rat dorsal CA1 hippocampal region. Degeneration was calculated by counting surviving neurons in the CA pyramidal layer using stereological methods. It was found that EMQMCM (5-10 nmol/1 µl) injected into the dorsal hippocampus 30 min, 1 h, or 3 h (the higher dose only) after KA significantly prevented the KA-induced neuronal degeneration. In vivo microdialysis studies in rat hippocampus showed that EMQMCM (100 µM) significantly increased γ-aminobutyric acid (GABA) and decreased glutamate release. When perfused simultaneously with KA, EMQMCM substantially increased GABA release and prevented the KA-induced glutamate release. The obtained results indicate that the mGluR1 antagonist, EMQMCM, may exert neuroprotection against excitotoxicity after delayed treatment (30 min to 6 h). The role of enhanced GABAergic transmission in the neuroprotection is postulated.
Asunto(s)
Apoptosis/efectos de los fármacos , Hipocampo/efectos de los fármacos , Ácido Kaínico/antagonistas & inhibidores , Fármacos Neuroprotectores/farmacología , Quinolinas/farmacología , Animales , Caspasa 3/metabolismo , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/patología , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Ácido Glutámico/metabolismo , Hipocampo/patología , Ácido Kaínico/administración & dosificación , Ácido Kaínico/toxicidad , L-Lactato Deshidrogenasa/metabolismo , Masculino , Ratones , Microinyecciones , Degeneración Nerviosa/inducido químicamente , Degeneración Nerviosa/patología , Cultivo Primario de Células , Quinolinas/administración & dosificación , Ratas , Ratas Wistar , Ácido gamma-Aminobutírico/metabolismoRESUMEN
Depression is a frequent comorbid disorder in Parkinson's disease (PD) which may precede appearance of its motor symptoms by several years. Pathomechanisms underlying PD have been suggested to be responsible for the PD-related depression. The aim of the study was to examine the influence of a partial lesion of striatal dopaminergic terminals on the "depressive-like" behavior of rats in the forced swimming test (FS). 6-Hydroxydopamine (6-OHDA) was injected bilaterally into the ventro-lateral region of the caudate-putamen (CP) (3.75 µg/2.5 µl/side). The locomotor activity and behavior of rats in the FS were measured 2 and 4 weeks after the operation. The lesion extent was analyzed by biochemical and immunohistochemical methods. Two weeks after the operation, the 6-OHDA-treated rats displayed a prolonged immobility in the FS. This effect disappeared after 4 weeks. The locomotor activity was not influenced by 6-OHDA. Levels of dopamine, DOPAC and HVA were decreased in the nucleus accumbens (NAC) 2 weeks after 6-OHDA but were not changed in the CP, frontal cortex (FCX) and substantia nigra (SN). No significant effect of 6-OHDA on tyrosine hydroxylase-immunoreactivity in the CP and NAC were found. The present study indicates that a relatively small lesion of dopaminergic terminals in the ventral striatum, which does not produce any motor disturbances, may induce "depressive-like" symptoms.
Asunto(s)
Ganglios Basales/metabolismo , Depresión/metabolismo , Dopamina/fisiología , Neuronas Dopaminérgicas/metabolismo , Animales , Ganglios Basales/efectos de los fármacos , Neuronas Dopaminérgicas/efectos de los fármacos , Neuronas Dopaminérgicas/patología , Masculino , Actividad Motora/efectos de los fármacos , Actividad Motora/fisiología , Oxidopamina/toxicidad , Ratas , Ratas WistarRESUMEN
Extensive research into glutamate receptors in the central nervous system has shown important role of metabotropic glutamate receptors (mGluR) as potential targets for neuroprotective drugs. The aim of the present study was to investigate neuroprotective potential of the highly selective mGlu5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]-pyridine (MTEP) against kainate (KA)-induced excitotoxicity in vivo. Our attention was focused mainly on the effectiveness of delayed treatment. In order to evoke neuronal injury, rats were unilaterally injected with kainic acid (KA; 2.5 nmol/1 µl) into the CA1 region of the hippocampus. MTEP (1, 5 or 10 nmol/1 µl) was administered into CA1 30 min, 1, 3 and 6 h after KA. Additionally, other rats were injected intraperitoneally (i.p.) with MTEP in a dose of 1 mg/kg, once daily for 7 days. The first injection of MTEP was 1 h after KA. Seven days after treatment, the brains were taken out and analyzed histologically to estimate the total number of neurons in CA region of dorsal hippocampus using stereological methods. The study was also aimed at determining a possible influence of MTEP on neuronal glutamate release induced by KA in the hippocampus, using microdialysis method. The obtained results showed that MTEP had neuroprotective effect after both intrahippocampal and intraperitoneal injection. It was found that MTEP could prevent excitotoxic neuronal damage even when it was applied 1-6 h after the toxin. Moreover, it was observed that MTEP significantly reduced the KA-induced glutamate release in the hippocampus. It seems to play a role in mediating neuroprotective effects of MTEP.
Asunto(s)
Región CA1 Hipocampal/efectos de los fármacos , Agonistas de Aminoácidos Excitadores/farmacología , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Piridinas/farmacología , Receptores de Glutamato Metabotrópico/antagonistas & inhibidores , Tiazoles/farmacología , Animales , Región CA1 Hipocampal/metabolismo , Tamaño de la Célula/efectos de los fármacos , Ácido Glutámico/metabolismo , Ácido Kaínico/farmacología , Masculino , Microdiálisis , Neuronas/metabolismo , Ratas , Ratas Wistar , Receptor del Glutamato Metabotropico 5 , Receptores de Glutamato Metabotrópico/metabolismo , Factores de TiempoRESUMEN
A(2A) adenosine receptor antagonists have been proposed as a new therapy for Parkinson's disease (PD). Since oxidative stress plays an important role in the pathogenesis of PD, we studied the effect of the selective A(2A) adenosine receptor antagonists 8-(3-chlorostyryl)caffeine (CSC) and 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM 241385) on L: -3,4-dihydroxyphenylalanine (L: -DOPA)-induced hydroxyl radical generation using in vivo microdialysis in the striatum of freely moving rats. L: -DOPA (100 mg/kg; in the presence of benserazide, 50 mg/kg) given acutely or repeatedly for 14 days generated a high level of hydroxyl radicals, measured by HPLC with electrochemical detection, as the product of their reaction with p-hydroxybenzoic acid (PBA). CSC (1 mg/kg) and ZM 241385 (3 mg/kg) decreased haloperidol (0.5 mg/kg)-induced catalepsy, while at low doses of 0.1 and 0.3 mg/kg, respectively, they did not display an effect. CSC (1 and 5 mg/kg) and ZM 241385 (3 and 9 mg/kg) given acutely, or CSC (1 mg/kg) and ZM 241385 (3 mg/kg) given repeatedly, increased the production of hydroxyl radicals in dialysates from rat striatum. Both acute and repeated administration of CSC (0.1 and 1 mg/kg) and ZM 241385 (3 mg/kg) decreased L: -DOPA-induced generation of hydroxyl radicals. However, a high single dose of either CSC (5 mg/kg) and ZM 241385 (9 mg/kg) markedly potentiated the effect of L: -DOPA on hydroxyl radical production. The increase in hydroxyl radical production by acute and chronic injection of CSC and ZM 241385 may be related to the increased release of dopamine (DA) and its metabolism in striatal dialysates. Similarly, increased DA release following a single high dose of CSC or ZM 241385 appears to be responsible for augmentation of L: -DOPA-induced hydroxyl radical formation. Conversely, the inhibition of L: -DOPA-induced production of hydroxyl radical by single and repeated low doses of CSC or repeated low doses of ZM 241385 may be related to reduced DA metabolism. Summing up, A(2A) antagonists, used as a supplement of L: -DOPA therapy, depending on the dose used, may have a beneficial or adverse effect on ongoing neurodegenerative processes and accompanying oxidative stress.
Asunto(s)
Antagonistas del Receptor de Adenosina A2 , Cuerpo Estriado/efectos de los fármacos , Dopaminérgicos/farmacología , Radical Hidroxilo/metabolismo , Levodopa/farmacología , Triazinas/farmacología , Triazoles/farmacología , Xantinas/farmacología , Ácido 3,4-Dihidroxifenilacético/metabolismo , Animales , Área Bajo la Curva , Benserazida/farmacología , Catalepsia/inducido químicamente , Catalepsia/tratamiento farmacológico , Cuerpo Estriado/metabolismo , Dopamina/metabolismo , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Haloperidol , Ácido Homovanílico/metabolismo , Masculino , Microdiálisis/métodos , Ratas , Ratas Wistar , Factores de TiempoRESUMEN
Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with selective loss of dopaminergic neurons in substantia nigra pars compacta. Among the proposed mechanisms of dopaminergic degeneration, oxidative stress is believed to play an important role. On the other hand, L-DOPA used as the main medication in PD and overproduction of dopamine (DA) in striatal neurons could elicit toxic effects due to formation of free radicals (FRs). Adenosine, an endogenous neuromodulator was shown in various experimental models to have neuroprotective properties. In our study, we investigated the role of adenosine A(1) and A(2A) receptor ligands in hydroxyl radical generation by L-DOPA in the rat striatum. The hydroxyl radical was assayed by HPLC-ED as a product of its reaction with p-hydroxybenzoic acid (PBA). Intrastriatal infusion of L-DOPA(50 microM) markedly increased dialysate level of DA and 3,4-dihydroxybenzoic acid (3,4-DHBA). An adenosine A(1) receptor agonist N(6)-cyclopentyladenosine (CPA, 25-50 microM), nonselectiveA(1)/A(2A) receptor agonist 2-chloroadenosine (2-CADO, 50-100 microM), and selective A(2A) receptor agonist CGS 21680 (25-50 microM) decreased the level of 3,4-DHBA. A non-selective A(1)/A(2A) adenosine receptor antagonist caffeine (100 microM) produced similar effect on 3,4-DHBA level. At the same time, CPA and 2-CADO, but not CGS 21680 or caffeine, decreased L-DOPA-induced DA release. The adenosine receptor ligands alone only weakly changed extracellular DA level and did not influence hydroxyl radical production. However, they showed scavenging activity in Fenton reaction in vitro. The primary caffeine metabolite in rodents, 1,3,7-trimethyl uric acid (1,3,7-mUA) decreased both, DA synthesis and 3,4-DHBA level. Thus, paradoxically, both agonists of A(1) receptor and agonist of A(2A) receptor as well as antagonist of A(1) and A(2A) receptors (caffeine), all decreased generation of FRs. Our study suggests that a decrease in hydroxyl radical generation caused by adenosine receptor ligands results from attenuation of L-DOPA-induced DA release or from their scavenging activity.